The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity

Researchers described the characterization of MiNK-215, an allogeneic human invariant NK T (iNKT) cell therapy in which iNKT cells were engineered to express an fibroblast activation protein (FAP)-targeting CAR and to secrete IL15 to remodel the tumor microenvironment and enhance antitumor activity.